» Articles » PMID: 29781755

More Robust Gut Immune Responses Induced by Combining Intranasal and Sublingual Routes for Prime-boost Immunization

Overview
Date 2018 May 22
PMID 29781755
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Norovirus causes acute and debilitating gastroenteritis, characterized by vomiting and diarrhea. We recently reported a recombinant GII. 4 P domain particle (Pd) vaccine adjuvanted with a flagellin, Vibrio vulnificus FlaB, effectively promoting both humoral and cell-mediated immune responses. In the previous study, we found that sublingual (SL) immunization induced higher fecal secretory IgA (SIgA) responses while intranasal (IN) route provided higher amplitude of humoral and cellular immune responses in the systemic compartment. We hypothesized that the combination of IN and SL routes should induce more potent and sustained SIgA responses in the gut. In this study, we have tried combinatorial prime-boost immunization employing both IN and SL routes. The IN priming and SL boosting with the Pd+FlaB vaccine enhanced highest SIgA responses in feces, accompanying increased Pd-specific memory B cells and plasma cells in spleen and bone marrow, respectively. Notably, the strongest long-lasting SIgA response in feces was induced by combined IN prime and SL boost vaccination, which was sustained for more than 3 months. Significantly enhanced gut-homing B cell and follicular helper T cell responses in mesenteric lymph nodes (mLNs) were observed in the IN prime and SL boost combination. IN priming was a requisite for the robust induction of Pd-specific IFNγ, IL-2, IL-4 and IL-5 cytokine responses in the systemic immune compartment. Collectively, the IN prime and SL boost combination was the best option for inducing balanced long-lasting immune responses against the norovirus antigen in both enteric and systemic compartments. These results suggest that immune responses in specific mucosal compartments may be programmed by employing different prime-boost immunization routes.

Citing Articles

Multi-Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation.

Freire Haddad H, Roe E, Xie Fu V, Curvino E, Collier J Adv Healthc Mater. 2024; 14(1):e2402546.

PMID: 39475070 PMC: 11695164. DOI: 10.1002/adhm.202402546.


Rapid and Highly Efficient Genetic Transformation and Application of Interleukin-17B Expressed in Duckweed as Mucosal Vaccine Adjuvant.

Tan X, Chen S, Fang Y, Liu P, Hu Z, Jin Y Biomolecules. 2022; 12(12).

PMID: 36551310 PMC: 9775668. DOI: 10.3390/biom12121881.


A sublingual nanofiber vaccine to prevent urinary tract infections.

Kelly S, Votaw N, Cossette B, Wu Y, Shetty S, Shores L Sci Adv. 2022; 8(47):eabq4120.

PMID: 36417519 PMC: 9683704. DOI: 10.1126/sciadv.abq4120.


Nanoclays: Promising Materials for Vaccinology.

Govea-Alonso D, Garcia-Soto M, Betancourt-Mendiola L, Padilla-Ortega E, Rosales-Mendoza S, Gonzalez-Ortega O Vaccines (Basel). 2022; 10(9).

PMID: 36146630 PMC: 9505858. DOI: 10.3390/vaccines10091549.


Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis.

Garcia-Del Rio L, Diaz-Rodriguez P, Pedersen G, Christensen D, Landin M Adv Healthc Mater. 2022; 11(11):e2102508.

PMID: 35124896 PMC: 11468966. DOI: 10.1002/adhm.202102508.


References
1.
Campbell D, Butcher E . Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med. 2002; 195(1):135-41. PMC: 2196018. DOI: 10.1084/jem.20011502. View

2.
Kim K, Lee Y, Hwang H, Kwon Y, Kim M, Ko E . Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T Cells. J Virol. 2015; 89(22):11692-705. PMC: 4645681. DOI: 10.1128/JVI.02018-15. View

3.
Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert R, McGhee J, Yuki Y . Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012; 11(3):367-79. PMC: 3315788. DOI: 10.1586/erv.11.196. View

4.
Ellyard J, Avery D, Phan T, Hare N, Hodgkin P, Tangye S . Antigen-selected, immunoglobulin-secreting cells persist in human spleen and bone marrow. Blood. 2004; 103(10):3805-12. DOI: 10.1182/blood-2003-09-3109. View

5.
KUKLIN N, ROTT L, Feng N, Conner M, Wagner N, Muller W . Protective intestinal anti-rotavirus B cell immunity is dependent on alpha 4 beta 7 integrin expression but does not require IgA antibody production. J Immunol. 2001; 166(3):1894-902. DOI: 10.4049/jimmunol.166.3.1894. View